YouTube · Q2 2026 · 2026-07-24
LH · NYSE
Labcorp
Diagnostics & Research · United States
USD 311.280.9% daily changeQuote 2026-10-06 · USD
- Market cap (USD)
- US$25.24B
- Trailing P/E
- 25.73x
- Forward P/E
- 15.69x
- Quarterly revenue growth
- 5.8%
- Trailing net margin
- 7.0%
- Indicated dividend yield
- 0.9%
Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-28 (provider estimate, not issuer-confirmed).
Company background
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Company websiteQ1 2026
Go beyond the headline.
Comparable businesses
LH peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | LHLabcorp Holdings Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | DGXQuest Diagnostics IncorporatedSnapshot 2026-10-06Financial period: 2026-06-30 | MTDMettler-Toledo International Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$25.24B | US$25.34B | US$31.31B | US$28.32Bn=2 |
| Forward P/EProvider forward earnings estimate | 15.69x | 19.04x | 30.20x | 24.62xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 13.68x | 14.03x | 25.85x | 19.94xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 5.8% | 10.2% | 4.5% | 7.3%n=2 |
| Operating marginLatest reported quarter | 12.2% | 15.2% | 31.2% | 23.2%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 3.5% | 3.6% | 2.2% | 2.9%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 2.88x | 2.55x | 1.64x | 2.09xn=2 |
| Debt / equityTotal debt / positive book equity | 0.79x | 0.81x | 166.68x | 83.75xn=2 |
| Trailing P/ETrailing twelve-month earnings | 25.73x | 24.37x | 35.22x | 29.79xn=2 |
| Price / bookPrice / positive book equity per share | 2.93x | 3.36x | 2,441.41x | 1,222.38xn=2 |
| EV / salesEnterprise value / trailing revenue | 2.21x | 2.75x | 7.98x | 5.36xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | 28.2% | 15.0% | 18.3% | 16.6%n=2 |
| Gross marginTrailing twelve months | 28.9% | 33.2% | 60.3% | 46.7%n=2 |
| Net marginTrailing twelve months | 7.0% | 9.2% | 21.9% | 15.5%n=2 |
| Return on equityProvider trailing return; positive equity only | 11.7% | 14.6% | — | — |
| Free cash flow marginTrailing free cash flow / revenue | 6.2% | 7.9% | 16.8% | 12.3%n=2 |
| Dividend yieldIndicated annual dividend / price | 0.9% | 1.5% | — | — |
| Earnings payoutProvider trailing dividend payout | 23.8% | 26.1% | 0.0% | 13.1%n=2 |
| Current ratioCurrent assets / current liabilities | 1.80x | 1.59x | 1.12x | 1.36xn=2 |
| BetaProvider historical market sensitivity | 0.85 | 0.54 | 1.19 | 0.86n=2 |
YouTube · Q2 2026 · 2026-07-24
YouTube · Q2 2026 · 2026-08-02
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for LH
Q1 20262026-05-04
LH Stock: Revenue Beats, EPS Misses — Q1 2026
Presentation · 2026-05-04 · YouTube